Sign inJoin waitlistJoin the waitlist

PD

Pamela Drullinsky

Attending Physician, Regional Care Network Medical Site Director, MSK Nassau · New York Presbyterian Hospital

Credentials: · · ·

History

Memorial Sloan Kettering Cancer Center
2019–Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
Mount Sinai Medical Center
Faculty of Medicine

Research

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label,…
The Lancet Oncology · 2021 · 278 citations
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of…
The Lancet · 2024 · 251 citations
Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer
Clinical Cancer Research · 1997 · 167 citations

AZ
Andrew Zelenetz
12 papers
AK
Anita Kumar
12 papers
Matthew Matasar
10 papers
PH
Paul Hamlin
10 papers
AM
Alison Moskowitz
9 papers
AN
Ariela Noy
9 papers
Craig Moskowitz
9 papers
DS
David Straus
8 papers
DL
Diana Lake
8 papers
JG
John Gerecitano
8 papers
AY
Anas Younes
7 papers
CH
Clifford Hudis
7 papers

Clinical trials

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2026–2030
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2008–2010